ELI LILLY AND COMPANY Total Assets
ELI LILLY AND COMPANY (LLY) had Total Assets of $142.28 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-08-05
- 2026-06-30: Assets $142.28B.
- 2026-03-31: Assets $116.58B.
- 2025-12-31: Assets $112.48B.
- 2025-09-30: Assets $114.94B.
| Period end | Assets | Assets as first filed |
|---|---|---|
| 2026-06-30 | $142.28B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $116.58B 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $112.48B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $114.94B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $100.92B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $89.39B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $78.72B 10-K · filed 2026-02-12 | $78.71B 10-K · filed 2025-02-19 |
| 2024-09-30 | $75.61B 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $71.87B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $63.94B 10-Q · filed 2024-04-30 | |
| 2023-12-31 | $64.01B 10-K · filed 2025-02-19 | |
| 2023-09-30 | $57.92B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $54.81B 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $53.16B 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $49.49B 10-K · filed 2024-02-21 | |
| 2022-09-30 | $47.46B 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $47.06B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $46.92B 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $48.81B 10-K · filed 2023-02-22 | |
| 2021-09-30 | $48.19B 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $47.81B 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $46.84B 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $46.63B 10-K · filed 2022-02-23 | |
| 2020-09-30 | $43.95B 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $41.97B 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $41.10B 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $39.29B 10-K · filed 2021-02-17 | |
| 2019-09-30 | $37.89B 10-Q · filed 2019-10-25 | |
| 2019-06-30 | $38.67B 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $38.01B 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $43.91B 10-K · filed 2020-02-19 | |
| 2018-09-30 | $44.63B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $42.36B 10-Q · filed 2018-07-25 | |
| 2018-03-31 | $44.36B 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $44.98B 8-K · filed 2019-10-24 | |
| 2017-09-30 | $43.01B 10-Q · filed 2017-10-27 | |
| 2017-06-30 | $40.95B 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $37.62B 10-Q · filed 2017-05-01 | |
| 2016-12-31 | $38.81B 10-K · filed 2018-02-20 | |
| 2016-09-30 | $37.59B 10-Q · filed 2016-10-28 | |
| 2016-06-30 | $36.48B 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $34.69B 10-Q · filed 2016-04-29 | |
| 2015-12-31 | $35.57B 10-K · filed 2017-02-21 | |
| 2015-09-30 | $36.30B 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $36.04B 10-Q · filed 2015-07-30 | |
| 2015-03-31 | $35.65B 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $36.31B 10-K · filed 2016-02-19 | $37.18B 10-K · filed 2015-02-19 |
| 2014-09-30 | $34.65B 10-Q · filed 2014-10-29 | |
| 2014-06-30 | $35.02B 10-Q · filed 2014-07-28 | |
| 2014-03-31 | $34.76B 10-Q · filed 2014-04-28 | |
| 2013-12-31 | $35.25B 10-K · filed 2015-02-19 | |
| 2013-09-30 | $33.97B 10-Q · filed 2013-10-30 | |
| 2013-06-30 | $33.23B 10-Q · filed 2013-07-26 | |
| 2013-03-31 | $32.30B 10-Q · filed 2013-04-26 | |
| 2012-12-31 | $34.40B 10-K · filed 2014-02-19 | |
| 2012-09-30 | $34.32B 10-Q · filed 2012-10-26 | |
| 2012-06-30 | $31.81B 10-Q · filed 2012-07-27 | |
| 2012-03-31 | $32.24B 10-Q · filed 2012-04-30 | |
| 2011-12-31 | $33.66B 10-K · filed 2013-02-21 | |
| 2011-09-30 | $33.04B 10-Q · filed 2011-10-28 | |
| 2011-06-30 | $32.78B 10-Q · filed 2011-07-29 | |
| 2011-03-31 | $31.70B 10-Q · filed 2011-04-29 | |
| 2010-12-31 | $31.00B 10-K · filed 2012-02-24 | |
| 2010-09-30 | $29.90B 10-Q · filed 2010-10-29 | |
| 2010-06-30 | $27.72B 10-Q/A · filed 2010-08-02 | |
| 2010-03-31 | $27.20B 10-Q · filed 2010-07-30 | |
| 2009-12-31 | $27.46B 10-K · filed 2011-02-22 | |
| 2009-09-30 | $27.13B 10-Q · filed 2009-10-30 | |
| 2009-06-30 | $26.93B 10-Q · filed 2009-07-31 | |
| 2008-12-31 | $29.21B 10-K · filed 2010-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |